Zacks Investment Research upgraded shares of Eiger Biopharmaceuticals (NASDAQ:EIGR) from a sell rating to a hold rating in a research note issued to investors on Thursday.
According to Zacks, “Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. “
Several other analysts have also recently commented on the company. Oppenheimer set a $26.00 target price on Eiger Biopharmaceuticals and gave the company a buy rating in a research report on Tuesday, January 16th. Ladenburg Thalmann Financial Services initiated coverage on Eiger Biopharmaceuticals in a research report on Wednesday, January 3rd. They issued a buy rating and a $32.00 target price on the stock. Piper Jaffray Companies restated an overweight rating and issued a $17.00 target price (down from $35.00) on shares of Eiger Biopharmaceuticals in a research report on Tuesday, January 16th. ValuEngine upgraded Eiger Biopharmaceuticals from a sell rating to a hold rating in a research report on Sunday, December 31st. Finally, Wedbush lowered their target price on Eiger Biopharmaceuticals from $36.00 to $34.00 and set an outperform rating on the stock in a research report on Thursday. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. Eiger Biopharmaceuticals has a consensus rating of Buy and an average price target of $27.25.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its earnings results on Monday, March 12th. The biotechnology company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.09). equities analysts anticipate that Eiger Biopharmaceuticals will post -4.44 earnings per share for the current year.
Several hedge funds have recently modified their holdings of EIGR. Prosight Management LP acquired a new position in shares of Eiger Biopharmaceuticals during the 4th quarter valued at $9,469,000. Jennison Associates LLC acquired a new position in shares of Eiger Biopharmaceuticals during the 4th quarter valued at $8,430,000. Armistice Capital LLC acquired a new position in shares of Eiger Biopharmaceuticals during the 4th quarter valued at $5,357,000. Stonepine Capital Management LLC acquired a new position in shares of Eiger Biopharmaceuticals during the 4th quarter valued at $2,093,000. Finally, Sphera Funds Management LTD. increased its position in shares of Eiger Biopharmaceuticals by 35.0% during the 3rd quarter. Sphera Funds Management LTD. now owns 520,269 shares of the biotechnology company’s stock valued at $5,723,000 after purchasing an additional 134,968 shares during the period. Institutional investors own 68.96% of the company’s stock.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.